Kidney Cancer

>

Latest News

There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.
Tivozanib Shows Efficacy in Pretreated Metastatic RCC

June 11th 2025

There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.
Machine Learning Approach May Predict Outcomes in RCC

June 4th 2025

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.
Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

June 2nd 2025

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.
Outpatient Robotic Partial Nephrectomy Is Safe/Feasible for Renal Tumors

April 29th 2025

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.
Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

April 6th 2025

More News